Contact Us

An innovative implant
aimed at treating open angle glaucoma

Choose CID for no ECL risk ‘by design’

Ciliatech’s groundbreaking CID (Cilio-Scleral Inter-positioning Device) technology proves that a significant IOP decrease can be achieved while leaving the anterior chamber untouched and without altering the eye’s anterior segment.

All other glaucoma implants, whatever the chosen outflow route (subconjunctival filtration, trabecular stent, cyclodialysis), penetrate the anterior chamber and remain partly in it. It is known by literature that any device close to the corneal endothelium is potentially harmful to corneal endothelial cells.

In contrast, a CID surgical procedure distances itself from the anterior chamber, making it a very safe and significantly different method to all intracameral implants. As there is no risk of a CID implant being in contact with, or close to, the cornea; there is, therefore, no ECL (corneal Endothelial Cell Loss) risk ‘by design’.

CID new implant

A safer alternative to effectively reduce IOP

As a CID implant is neither in contact with, nor close to, the cornea, a CID surgery:

  • Incurs no ECL: the implant does not enter the anterior chamber of the eye, as the wall that separates the anterior chamber from the supraciliary space is not cut: there is zero risk of altering the corneal endothelium
  • Generates very low post-operative inflammation; the surgical technique and the implant do not provoke ciliary body reaction: the anatomical compartments of the anterior segment are not modified, resulting in fewer adverse events and thus better patient post-operative comfort
  • Does not create a bleb: scleral incisions are sutured watertight to maintain the outflow under the sclera. As such, the surgical technique and the implant cannot generate a subconjunctival bleb and its associated complications (heavy post-op monitoring, cyst, fibrosis, use of antimetabolites, etc.)
  • ‘No loss of chance’: should a second surgery be needed, CID surgery preserves the eye anatomy (anterior segment and conjunctiva); another interventional act (laser, stent, trabeculectomy or GDD) can be performed without difficulty

Key design elements

Ciliatech’s CID implant is a non-resorbable implant which remains in place for the patient’s lifetime.
It is a one-piece of 26% hydrophilic acrylic, a raw material widely used in the manufacturing of intra-ocular lenses, which ensures long-term biocompatibility.

It consists of a specifically designed 6mm large, 4 mm wide, and 200µm thick plate*. The device’s two faces and edges are designed with grooves and corrugations to maximise the outflow from the anterior chamber and its circulation to the choroid and the sclera-conjunctival vessels

*Patent pending

Performance of Ciliatech’s CID implant**

  • Achieves an IOP in the mid to low teens (15 mmHg and lower)
  • Significant IOP reduction >33%
  • Medication reduction >90% at 12 months
  • No treatment failure (no reoperation) at 12 months in 42 patients: 89% of patients were medication free

**Based on internal data: interim results at 12M / 6M follow-up SAFARI 1 / SAFARI 2 studies resp.

178 Route de Cran Gevrier PAE Altaïs, C/O PEPINIERE GALILEO 74650 Chavanod – France

Contact Us

Terms of use – Privacy Policy